Matthias Müller, Dr. rer. nat.

Position: Staff Scientist (AkadR)

Room no.: CP-02-109

Telephone no.: +49 (0)231 755 7066

Member of the group since: 03/2017

University Degree: Dr. rer. nat. in Biochemistry at the Max Planck Institute of Molecular Physiology

 

Earlier positions: PhD student and IMPRS fellow at the Max Planck Institute of Molecular Physiology (“Mechanismen der reversiblen enzymatischen Adenylylierung von Rab‐Proteinen”) under supervision of Prof. Dr. Roger S. Goody and Prof. Dr. Aymelt Itzen, Post-Doctoral fellow (with Prof. Dr. Roger S. Goody)

Diplom-Biochemiker, Martin-Luther-Universität Halle-Wittenberg

Expertise: X-Ray Crystallography, Biophysics

Off-Lab activities (hobbies): traveling, climbing

 

Publications:

  1. Goebel, L.; Müller, M. P.; Goody, R. S.; Rauh, D.. KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Med. Chem. 2020, 11 (7), 760–770.

    DOI

  2. Lategahn, J.; Hardick, J.; Grabe, T.; Niggenaber, J.; Jeyakumar, K.; Keul, M.; Tumbrink, H. L.; Becker, C.; Hodson, L.; Kirschner, T.; Klövekorn, P.; Ketzer, J.; Baumann, M.; Terheyden, S.; Unger, A.; Weisner, J.; Müller, M. P.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J. Med. Chem. 2020, 63 (20), 11725–11755.

    DOI PubMed

  3. Baumann, M.; Depta, L.; Dienstbier, N.; Gontla, R.; Günther, G.; Hahn, S. A.; Hardick, J.; Hengstler, J. G.; Ladigan, S.; Landel, I.; Lindemann, M.; Maghnouj, A.; Müller, H.; Müller, M. P.; Pohl, M.; Quambusch, L.; Rauh, D.; Reintjes, C.; Scheinpflug, R.; Schultz-Fademrecht, C.; Siveke, J. T.; Smith, S.; Tannapfel, A.; Teschendorf, C.; Trajkovic-Arsic, M.; Uhl, W.; Uhlenbrock, N.; Unger, A.; Viebahn, R.; Weisner, J.; Wolters, H.. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Res. 2019, 79 (9), 2367–2378.

    DOI PubMed

  4. Goody, R. S.; Müller, M. P.; Rauh, D.. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules. Cell Chem. Biol. 2019, 26 (10), 1338–1348.

    DOI PubMed

  5. Lategahn, J.; Keul, M.; Klövekorn, P.; Tumbrink, H. L.; Niggenaber, J.; Müller, M. P.; Hodson, L.; Flaßhoff, M.; Hardick, J.; Grabe, T.; Engel, J.; Schultz-Fademrecht, C.; Baumann, M.; Ketzer, J.; Mühlenberg, T.; Hiller, W.; Günther, G.; Unger, A.; Müller, H.; Heimsoeth, A.; Golz, C.; Blank-Landeshammer, B.; Kollipara, L.; Zahedi, R. P.; Strohmann, C.; Hengstler, J. G.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chem. Sci. 2019, 10 (46), 10789–10801.

    DOI PubMed

  6. a) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. Angew. Chem. Int. Ed Engl. 2019, 58 (52), 18823–18829.

    DOI PubMed

    b) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity. Angew. Chem. 2019, 131 (52), 18999–19005.

    DOI

  7. Rai, A.; Goody, R. S.; Müller, M. P.. Multivalency in Rab effector interactions. Small GTPases 2019, 10 (1), 40–46.

    DOI PubMed

  8. Schehr, M.; Ianes, C.; Weisner, J.; Heintze, L.; Müller, M. P.; Pichlo, C.; Charl, J.; Brunstein, E.; Ewert, J.; Lehr, M.; Baumann, U.; Rauh, D.; Knippschild, U.; Peifer, C.; Herges, R.. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach. Photochem. Photobiol. Sci. 2019, 18 (6), 1398–1407.

    DOI PubMed

  9. Uhlenbrock, N.; Smith, S.; Weisner, J.; Landel, I.; Lindemann, M.; Le, T. A.; Hardick, J.; Gontla, R.; Scheinpflug, R.; Czodrowski, P.; Janning, P.; Depta, L.; Quambusch, L.; Müller, M. P.; Engels, B.; Rauh, D.. Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chem. Sci. 2019, 10 (12), 3573–3585.

    DOI PubMed

  10. Ali, I.; Eu, S.; Koch, D.; Bleimling, N.; Goody, R. S.; Müller, M. P.. Structure of the tandem PX-PH domains of Bem3 from Saccharomyces cerevisiae. Acta Crystallogr. F 2018, 74 (Pt 5), 315–321.

    DOI PubMed

  11. Jeganathan, S.; Müller, M. P.; Ali, I.; Goody, R. S.. Assays for Nucleotide Competitive Reversible and Irreversible Inhibitors of Ras GTPases. Biochemistry 2018, 57 (31), 4690–4699.

    DOI PubMed

  12. Müller, M. P.; Goody, R. S.. Molecular control of Rab activity by GEFs, GAPs and GDI. Small GTPases 2018, 9 (1-2), 5–21.

    DOI PubMed

  13. Müller, M. P.; Rauh, D.. Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation. Cell Chem. Biol. 2018, 25 (1), 4–6.

    DOI PubMed

  14. a) Tesch, R.; Becker, C.; Müller, M. P.; Beck, M. E.; Quambusch, L.; Getlik, M.; Lategahn, J.; Uhlenbrock, N.; Costa, F. N.; Polêto, M. D.; Pinheiro, P. d. S. M.; Rodrigues, D. A.; Sant'Anna, C. M. R.; Ferreira, F. F.; Verli, H.; Fraga, C. A. M.; Rauh, D.. An Unusual Intramolecular Halogen Bond Guides Conformational Selection. Angew. Chem. Int. Ed Engl. 2018, 57 (31), 9970–9975.

    DOI PubMed

    b) Tesch, R.; Becker, C.; Müller, M. P.; Beck, M. E.; Quambusch, L.; Getlik, M.; Lategahn, J.; Uhlenbrock, N.; Costa, F. N.; Polêto, M. D.; Pinheiro, P. d. S. M.; Rodrigues, D. A.; Sant'Anna, C. M. R.; Ferreira, F. F.; Verli, H.; Fraga, C. A. M.; Rauh, D.. Eine ungewöhnliche intramolekulare Halogenbindung führt zu konformationeller Selektion. Angew. Chem. 2018, 130 (31), 10120–10126.

    DOI

  15. Wolle, P.; Müller, M. P.; Rauh, D.. Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level. ACS Chem. Biol. 2018, 13 (3), 496–499.

    DOI PubMed

  16. Bührmann, M.; Wiedemann, B. M.; Müller, M. P.; Hardick, J.; Ecke, M.; Rauh, D.. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PloS one 2017, 12 (9), e0184627.

    DOI PubMed

  17. a) Cigler, M.; Müller, T. G.; Horn-Ghetko, D.; Wrisberg, M.-K. von; Fottner, M.; Goody, R. S.; Itzen, A.; Müller, M. P.; Lang, K.. Proximity-Triggered Covalent Stabilization of Low-Affinity Protein Complexes In Vitro and In Vivo. Angew. Chem. Int. Ed Engl. 2017, 56 (49), 15737–15741.

    DOI PubMed

    b) Cigler, M.; Müller, T. G.; Horn-Ghetko, D.; Wrisberg, M.-K. von; Fottner, M.; Goody, R. S.; Itzen, A.; Müller, M. P.; Lang, K.. Proximitäts-vermittelte kovalente Stabilisierung niedrig-affiner Proteinkomplexe in vitro und in vivo. Angew. Chem. 2017, 129 (49), 15943–15947.

    DOI

  18. Goody, R. S.; Müller, M. P.; Wu, Y.-W.. Mechanisms of action of Rab proteins, key regulators of intracellular vesicular transport. Biol. Chem. 2017, 398 (5-6), 565–575.

    DOI PubMed

  19. Koch, D.; Rai, A.; Ali, I.; Bleimling, N.; Friese, T.; Brockmeyer, A.; Janning, P.; Goud, B.; Itzen, A.; Müller, M. P.; Goody, R. S.. A pull-down procedure for the identification of unknown GEFs for small GTPases. Small GTPases 2016, 7 (2), 93–106.

    DOI PubMed

  20. Mueller, M. P.; Goody, R. S.. Review: Ras GTPases and myosin: Qualitative conservation and quantitative diversification in signal and energy transduction. Biopolymers 2016, 105 (8), 422–430.

    DOI PubMed

  21. Rai, A.; Oprisko, A.; Campos, J.; Fu, Y.; Friese, T.; Itzen, A.; Goody, R. S.; Gazdag, E. M.; Müller, M. P.. bMERB domains are bivalent Rab8 family effectors evolved by gene duplication. eLife 2016, 5.

    DOI PubMed

  22. Wiegandt, D.; Vieweg, S.; Hofmann, F.; Koch, D.; Li, F.; Wu, Y.-W.; Itzen, A.; Müller, M. P.; Goody, R. S.. Locking GTPases covalently in their functional states. Nat. Commun. 2015, 6, 7773.

    DOI PubMed

  23. Müller, M. P.; Albers, M. F.; Itzen, A.; Hedberg, C.. Exploring adenylylation and phosphocholination as post-translational modifications. ChemBioChem 2014, 15 (1), 19–26.

    DOI PubMed

  24. Goody, P. R.; Heller, K.; Oesterlin, L. K.; Müller, M. P.; Itzen, A.; Goody, R. S.. Reversible phosphocholination of Rab proteins by Legionella pneumophila effector proteins. EMBO J. 2012, 31 (7), 1774–1784.

    DOI PubMed

  25. Müller, M. P.; Shkumatov, A. V.; Oesterlin, L. K.; Schoebel, S.; Goody, P. R.; Goody, R. S.; Itzen, A.. Characterization of enzymes from Legionella pneumophila involved in reversible adenylylation of Rab1 protein. J. Biol. Chem. 2012, 287 (42), 35036–35046.

    DOI PubMed

  26. Stein, M.-P.; Müller, M. P.; Wandinger-Ness, A.. Bacterial pathogens commandeer Rab GTPases to establish intracellular niches. Traffic 2012, 13 (12), 1565–1588.

    DOI PubMed

  27. Goody, R. S.; Müller, M. P.; Schoebel, S.; Oesterlin, L. K.; Blümer, J.; Peters, H.; Blankenfeldt, W.; Itzen, A.. The versatile Legionella effector protein DrrA. Commun. Integr. Biol. 2011, 4 (1), 72–74.

    DOI PubMed

  28. a) Smit, C.; Blümer, J.; Eerland, M. F.; Albers, M. F.; Müller, M. P.; Goody, R. S.; Itzen, A.; Hedberg, C.. Efficient synthesis and applications of peptides containing adenylylated tyrosine residues. Angew. Chem. Int. Ed Engl. 2011, 50 (39), 9200–9204.

    DOI PubMed

    b) Smit, C.; Blümer, J.; Eerland, M. F.; Albers, M. F.; Müller, M. P.; Goody, R. S.; Itzen, A.; Hedberg, C.. Effiziente Synthese und Anwendung von Peptiden mit adenylylierten Tyrosinresten. Angew. Chem. 2011, 123 (39), 9367–9371.

    DOI

  29. Müller, M. P.; Peters, H.; Blümer, J.; Blankenfeldt, W.; Goody, R. S.; Itzen, A.. The Legionella effector protein DrrA AMPylates the membrane traffic regulator Rab1b. Science 2010, 329 (5994), 946–949.

    DOI PubMed

Go back